Geron jumps as its J&J-partnered cancer drug shows promise in Phase II

Damian Garde

Long-troubled developer is touting what it calls "unprecedented" early results for its lead drug, sending the biotech's share price up as it moves forward with partner Johnson & Johnson.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS